Optimised Patient Experience Workstream
Patients are at the heart of everything we do. We work with our lay partners in ‘co-production’ which ensures that the research which we conduct is driven by the needs of patients, their families and carers, and of the community as a whole. This includes working together to ensure that the best interests of patients are always foremost in our research and to design innovative studies which prioritise their personal values and preferences at the centre of their personalised treatment plan. This is particularly important in the setting of advanced disease, where eradicating the cancer may no longer be possible. In this case we want to find the best ways to balance a patient’s quantity and quality of life to suit their individual wishes.
Personalised, physiological, pre-treatment assessment
Current methods for determining an individual patient’s underlying fitness and predicting their tolerance of potentially toxic treatments are crude and prone to bias. We are assessing the relationship between a patient’s tolerance of treatment and other aspects of their well-being, such as how it affects their ability to perform tasks, their metabolism, inflammatory response and physiological assessments.
Assessment of individual patient experiences, during and after treatment
We extend our previous work on patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) to patients undergoing chemotherapy for advanced lung cancer who have a curative prognosis.
We are exploring difficult treatment decisions, assessing patient experience before and during treatments, and in the recovery phase. Patients who have opted not to undergo treatment will be an important comparator group.
Integration of patient experience into clinical decision-making
We will work with UK partners to classify subjective patient experience for use in clinical decision making. Our innovative ‘decision support model’ will be at the heart of a new concept in Multi-Disciplinary Team meetings – ‘SMART MDTs’. These SMART MDTs will co-produce personalised treatment plans based upon data, including tumour characteristics, the patient’s physiological resilience and individual values and preferences.